Investing in cannabis could gain cross-industry support if pharmaceutical applications expand. FDA exploratory guidelines in medical cannabis research could open the door for biotech collaborations, influencing valuation models for dual-market cannabis companies. The big question is, can this rally continue? With earnings set to come out next week, on Oct. 9, there could soon be another catalyst to look out for. If Tilray shows progress and is able to improve its financials, that may lead to even further gains. But if that isn't the case, then there may be some pullback. Investment strategy — do they take minority stakes, seek control, or follow-on in later rounds? The latest U.S. retail cannabis sales data hit $3.7B in March 2024, a record high since legalization waves began. Investing in cannabis now aligns with the bullish sentiment driven by rising transaction volumes and reduced oversupply issues, a factor improving stock performance stability.
